Pharmacologic Vitamin C Enhances Radiation Response in Pancreatic Cancer
Pharmacologic Vitamin C Enhances Radiation Response in Pancreatic Cancer
Pancreatic cancer is often treated with radiation therapy, but effectiveness can be limited by both tumor resistance and damage to surrounding healthy tissues. Alexander and colleagues investigated whether high-dose intravenous vitamin C (pharmacologic ascorbate) could simultaneously enhance tumor sensitivity to radiation while protecting normal tissues.
This study combined laboratory experiments with animal models of pancreatic cancer to evaluate the effects of pharmacologic ascorbate given alongside radiation therapy. High concentrations of vitamin C were administered to achieve pro-oxidant effects, generating hydrogen peroxide selectively in tumor tissues. Researchers assessed tumor response, oxidative stress markers, and indicators of normal tissue toxicity following radiation exposure.
The findings showed that pharmacologic ascorbate enhanced the cytotoxic effects of radiation in pancreatic tumor cells, leading to increased tumor cell death and improved tumor control in preclinical models. At the same time, vitamin C appeared to reduce radiation-induced damage in normal tissues, suggesting a dual effect of tumor radiosensitization and normal tissue protection.
Although these results are based on preclinical models, they provide strong mechanistic support for the use of high-dose intravenous vitamin C as an adjunct to radiation therapy. The study highlights a promising therapeutic strategy that may improve treatment effectiveness while reducing side effects, supporting further investigation in clinical trials involving patients with pancreatic cancer.
Reference:
Alexander MS, Wilkes JG, Schroeder SR, Buettner GR, Wagner BA, Du J, Gibson-Corley K, O’Leary BR, Spitz DR, Buatti JM, Berg DJ, Bodeker KL, Vollstedt S, Brown HA, Allen BG, Cullen JJ. Pharmacologic ascorbate reduces radiation-induced normal tissue toxicity and enhances tumor radiosensitization in pancreatic cancer. Cancer Res. 2018;78(24):6838–6851. doi:10.1158/0008-5472.CAN-18-1680. PMID: 30254147; PMCID: PMC6295907.
